Minnesota FOIA #N009349301

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

This purchase order, issued by the Twin Cities, is awarded to Oklahoma Medical Research Foundation for the procurement of Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia. The order, dated October 30, 2023, involves a single line item with an obligated amount of $17,434. The vendor, Oklahoma Medical Research Foundation, is located in Oklahoma City, Oklahoma, with address 825 NE 13TH ST, ZIP 73104-5005. The procurement appears to be a direct contract for medical research supplies or treatment, with no specific contract duration noted. The award is part of a single-transaction purchase, with no mention of projected competitors.

Description

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia